BTG Plc, a London-based specialty pharmaceuticals company, has acquired Protherics Plc, a developer of new immunotherapeutic products and therapies, for an undisclosed sum.

BTG Plc, a London-based specialty pharmaceuticals company, has acquired Protherics Plc, a developer of new immunotherapeutic products and therapies, for an undisclosed sum.

BTG has confirmed that Rolf Soderstrom, finance director of Protherics, has joined BTG’s board as chief financial officer replacing Christine Soden, who becomes chief operating officer.

Louise Makin, BTG’s CEO commented: “We are delighted to have completed this merger with Protherics, which gives us the platform to build a leading specialty pharmaceuticals business.

“Initial integration activities will focus on prioritising programmes in the development pipeline and rationalising operations to achieve the planned synergies and cost savings,” she added.

BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists.